Panmure Gordon upgraded shares of Calyxt (OTCMKTS:HZNQF) from a hold rating to a buy rating in a research note issued to investors on Thursday morning, The Fly reports.
Separately, Stifel Nicolaus downgraded shares of Calyxt from a buy rating to a hold rating in a report on Monday, April 27th.
Calyxt stock opened at $1.34 on Thursday. The firm’s fifty day simple moving average is $1.29. Calyxt has a 1-year low of $1.20 and a 1-year high of $2.49.
Calyxt Company Profile
Horizon Discovery Group plc, a translational genomics company, develops and supplies patient-relevant drug discovery and diagnostic reference standards in the Americas, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. It operates a translational genomics platform, a suite of gene editing tools to alter gene sequence in human or mammalian cell-lines.
Featured Story: What strategies should day traders use to execute a trade?
Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.